Answers are grounded in this paper and cite their sources.
Background: Alcohol-associated liver disease (ALD) heavily contributes to global alcohol-associated mortality. Alcohol synergizes with other causes of liver disease, such as a Western diet rich in fat, fructose, and cholesterol. However, the role of individual dietary components in ALD development is not fully understood. We aimed to study the role of cholesterol in ALD development. Methods: Mice were fed ad libitum with a high-cholesterol diet with 20% EtOH in the drinking water for 10 weeks. To assess the drivers of ALD in males, we performed spatial transcriptomics (Xenium, 10x Genomics). Results: Compared with a high-cholesterol diet alone, alcohol-treated mice showed elevated serum ALT and AST, increased inflammation, fibrosis, ductular reaction, and reduced HNF4α and albumin production. In female mice, we found that alcohol promoted pro-inflammatory cytokine production and Tgfb1 expression, thus driving liver injury and fibrosis. In males, we observed that fibrosis and liver injury were induced by other mechanisms. We found that the liver adapted to a high-cholesterol diet by increasing cholesterol metabolism in hepatocytes. In contrast, alcohol impaired liver adaptation to a high-cholesterol diet by reducing cholesterol metabolism, HDL production, and hepatic cholesterol secretion, thus driving inflammation and fibrosis. Alcohol-treated mice showed a significant decrease in Apoa1 , Abcg8 , Cyp7b1 , Saa1 , and Saa2 , and reduced serum HDL-C, SAA, and 27-hydroxycholesterol. Low 27-hydroxycholesterol in patients with cirrhosis is associated with increased MELD scores and poor transplant-free survival. Hepatocyte-specific Kdm5b knockout mice were protected from alcohol effects by restoring cholesterol secretion in part through an upregulation of Abcg8 . Accordingly, these mice were protected against alcohol-induced fibrosis development. Conclusion: In summary, alcohol impairs liver adaptation to a high-cholesterol diet. Restoring the adaptation by KDM5B inhibition may be beneficial for patients with ALD.
No takes yet. Share an insight, caveat, or question.
Mah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: